HOOKIPA Pharma Inc. (HOOK) Reports Promising Anti-Tumor Activity & Favorable Tolerability for Phase 1 Monotherapy Data of HB-201 for Treatment of Advanced HPV16+ Cancers

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/1/2026

1. NKE
2. SPY
3. AVAV
4. NVDA
5. MU
6. DLR
7. EOSE
8. TSLA
9. ABVX
10. AAPL

Go back to HOOKIPA Pharma Inc. (HOOK) Reports Promising Anti-Tumor Activity & Favorable Tolerability for Phase 1 Monotherapy Data of HB-201 for Treatment of Advanced HPV16+ Cancers

HOOKIPA Interim Phase 1 Monotherapy Data of HB-201 for the Treatment of Advanced HPV16+ Cancers Shows Promising Anti-Tumor Activity and Favorable Tolerability

December 7, 2020 6:00 AM EST

Results support first proof of concept for HOOKIPAs replicating investigational single-vector immunotherapy in oncology

Data demonstrate responses and stable disease in some head and neck cancer patients who all received at least two prior therapies and progressed on a PD1 inhibitor

By targeting an antigen common to Human Papillomavirus 16-positive (HPV16+), HB-201 has the potential to be a tumor-agnostic therapy for all HPV16+ cancers

NEW YORK and VIENNA, Austria, Dec. 07,... More